Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Longevity
Biotech
Anti-aging biotech NewLimit nabs $435M to rejuvenate old cells
Backed by Peter Thiel's Founders Fund, NewLimit looks to push a liver-targeting mRNA therapeutic into the clinic next year.
Darren Incorvaia
Jun 2, 2026 1:00pm
ARPA-H designates up to $144M for anti-aging medical research
Feb 25, 2026 11:55am
GLP-1 enthusiasm pushes BioAge into new age with $170M series D
Feb 13, 2024 8:00am
AgeX keeps defying time to survive multiyear cash crunch
Aug 15, 2023 7:00am
Life Bio gene therapy restores visual function in primates
Apr 25, 2023 10:38am
Despite blockbuster Altos funds, longevity investment falls $1B
Jan 31, 2023 11:28am
